AHA president has asked Congress to intervene and demand HHS take a position on “drug companies’ attempts to hijack the 340B ...

John writes about the politics of health care, and he is the author of the twice-weekly D.C. Diagnosis newsletter. You can reach John on Signal at John_Wilkerson.07. WASHINGTON — The chair of the ...

After years of investigation, the outgoing chairman of the Senate Health, Education, Labor and Pensions Committee has ...

The Government Accountability Office believes Congress should slash the financial incentives the government pays hospitals in the 340B drug program, it said in a new report, over concerns that ...

The drugmaker stopped paying 340B discounts to hospitals that didn’t comply with its new paperwork requirements late last ...

Long-term 340B participation is linked to stronger financial assets, with much of the program’s recent growth flowing ...

In the latest legal development in the ongoing 340B contract pharmacy litigation, the United States Court of Appeals for the District of Columbia Circuit ruled earlier this week that the 340B Drug ...

The 340B Drug Pricing Program (340B Program) is no stranger to controversy. We have previously covered the ongoing contract pharmacy legal battles and the new alternative dispute resolution process.

Spending on drugs purchased at discounted 340B prices across all participating facilities went up 19% annually between 2010 and 2021, according to a June 17 report from the Congressional Budget Office ...

Examining the drivers of 340B drug program growth, the impact of vertical integration and contract pharmacies, the ongoing legal and regulatory disputes, and the strategic considerations life sciences ...

A clear look at the 340B program: how hospitals generate revenue from drug discounts, why it has expanded, and the growing ...

Under the 340B program, drug manufacturers provide medicines at steep discounts, which providers are supposed to pass on to vulnerable patients.